Kidney Transplantation Clinical Trial
Official title:
Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy
Verified date | February 2010 |
Source | University of Manitoba |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
The purpose of this study is to determine whether treatment with sirolimus, in combination
with low-dose tacrolimus and prednisone, is effective for the treatment of chronic allograft
nephropathy (progressive scarring) in children who have previously received a kidney
transplant. This treatment is compared to the standard therapy which uses low-dose
tacrolimus, mycophenolate mofetil and prednisons.
This study is a pilot study that will determine whether treatment with sirolimus reduces or
improves the rate of scarring seen on kidney biopsy of the transplanted kidney over time,
compared to children who continue to be treated with mycophenolate mofetil.
Status | Completed |
Enrollment | 40 |
Est. completion date | October 2008 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: - All male or female patients aged less than 17 years. - The patient has undergone a kidney transplant, from a cadaveric or living donor with compatible ABO blood type. - The patient is more than 12 months post-transplantation. - The allograft demonstrates histological changes consistent with CAN according to the Banff 97 classification schema (minimum of ct1 and ci1 score for tubular atrophy and interstitial fibrosis respectively). Exclusion Criteria: - The patient, or in case the patient is minor, the patient's parent(s) or their legal representative, has been fully informed and will not give informed consent to participate in the study. - The allograft demonstrates histological changes at the time of enrollment consistent with acute allograft rejection Grade Ia or worse, according to the Banff 97 classification schema (minimum of t2 and i2 score for tubulitis and interstitial inflammation respectively). - The patient is known to be allergic or intolerant to MMF, sirolimus or any of their known metabolites. - The patient for who routine protocol kidney biopsy is contraindicated. - Patients whose maintenance immunosuppression does not include both tacrolimus and prednisone at the time on study enrollment. - Patients previously treated with sirolimus. - The patient requires ongoing dosing with a systemic immunosuppressive drug at study entry for any reason other than kidney transplantation. - The patient and/or donor is known to be HIV or HCV positive. - The patient has significant liver disease, defined as having during the past 28 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site. - The patient has persistent leukopenia (WBC <3.0 x109/L). - The patient has persistent thrombocytopenia (<100 x109/L). - The patient has pre-existing significant hyperlipidemia (total cholesterol >7.8 mmol/L), not responding to medical therapy. - The patient has pre-existing elevated triglycerides, not responding to medical therapy. - The patient with malignancy or history of malignancy except for successfully treated Wilm's tumor (2 years) or non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully. - The patient has significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting or active peptic ulcer. - The patient has previously received or is receiving an organ transplant other than kidney. - The patient is taking or has been taking an investigational drug in the past 28 days or is currently participating in another clinical intervention trial. - Patients with the relapsing, non-diarrheal form of haemolytic-uraemic syndrome. - The patient is unlikely to comply with the protocol. - The patient has any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may invalidate communication with the investigator - Sexually active female patients who are pregnant or lactating or who do not consent to effective birth control. - The patient is less than 6 years of age. - The patient has significant and persistent EBV activity as measured by PCR amplification from blood samples. - The patient has a prior history of post-transplant lymphoproliferative disease. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Children's Hospital | Winnipeg | Manitoba |
Lead Sponsor | Collaborator |
---|---|
University of Manitoba | Wyeth is now a wholly owned subsidiary of Pfizer |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | histological quantification of interstitial fibrosis at 2 years | |||
Secondary | Renal function at 1 and 2 years. | |||
Secondary | Proteinuria at 2 years. | |||
Secondary | Freedom from acute rejection and graft loss over the 2 year study period. | |||
Secondary | Cumulative incidence and prevalence of adverse events and serious adverse events over the 2-year study period. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT02723591 -
To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT05945511 -
Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
|
||
Completed |
NCT02234349 -
Bile Acids and Incretins in Pancreas Kidney Transplant Patients
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT05917795 -
Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT05934383 -
Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension
|
N/A | |
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Not yet recruiting |
NCT04540640 -
Oxygenated Machine Preservation in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT03090828 -
Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease
|
N/A | |
Recruiting |
NCT02908139 -
Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients
|
N/A | |
Completed |
NCT02560558 -
Bela 8 Week Dosing
|
Phase 4 | |
Terminated |
NCT02417870 -
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT02154815 -
Pre-emptive Kidney Transplantation Quality of Life
|
N/A | |
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Enrolling by invitation |
NCT01905514 -
ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients
|
N/A | |
Completed |
NCT02147210 -
Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1
|
N/A | |
Recruiting |
NCT01699360 -
The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients
|
Phase 4 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
Completed |
NCT01672957 -
ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil)
|
N/A |